Complete response to ipilimumab and nivolumab therapy in a patient with extensive extrapulmonary high-grade small cell carcinoma of the pancreas and HIV infection

Muhammad Husnain, Wungki Park, Juan Carlos Ramos, Thomas Johnson, Joseph Chan, Arvind Dasari, Raja Mudad, Peter Hosein

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Immune checkpoint inhibitors (CPIs) have shown promising results in many solid tumors. There are limited data on the safety and efficacy of these drugs in HIV infected patients as they have traditionally been excluded from CPIs clinical trials. Case presentation: We present a case of an HIV-positive patient with extensive extrapulmonary high-grade small cell carcinoma who was treated with dual CPIs (nivolumab and ipilimumab) with a complete response to therapy and with a manageable safety profile. We performed a comprehensive literature review identifying 62 total HIV positive cases treated with CPIs showing this to be a potentially safe option in HIV-positive patients. Conclusion: HIV infection is not an absolute contraindication to CPI therapy. Our case and others provide justification for ongoing trials of CPI therapy in patients with HIV infection, a group that has traditionally been excluded from clinical trials.

Original languageEnglish (US)
Article number66
JournalJournal for ImmunoTherapy of Cancer
Volume6
Issue number1
DOIs
StatePublished - Jul 9 2018

Fingerprint

Small Cell Carcinoma
HIV Infections
Pancreas
HIV
Clinical Trials
Safety
Therapeutics
ipilimumab
nivolumab
Pharmaceutical Preparations
Neoplasms

Keywords

  • Check point inhibitors
  • HIV
  • Immunotherapy
  • Neuroendocrine carcinoma
  • Small cell cancer

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

@article{d213a8d4b7504d2fa4042a6c78c417db,
title = "Complete response to ipilimumab and nivolumab therapy in a patient with extensive extrapulmonary high-grade small cell carcinoma of the pancreas and HIV infection",
abstract = "Background: Immune checkpoint inhibitors (CPIs) have shown promising results in many solid tumors. There are limited data on the safety and efficacy of these drugs in HIV infected patients as they have traditionally been excluded from CPIs clinical trials. Case presentation: We present a case of an HIV-positive patient with extensive extrapulmonary high-grade small cell carcinoma who was treated with dual CPIs (nivolumab and ipilimumab) with a complete response to therapy and with a manageable safety profile. We performed a comprehensive literature review identifying 62 total HIV positive cases treated with CPIs showing this to be a potentially safe option in HIV-positive patients. Conclusion: HIV infection is not an absolute contraindication to CPI therapy. Our case and others provide justification for ongoing trials of CPI therapy in patients with HIV infection, a group that has traditionally been excluded from clinical trials.",
keywords = "Check point inhibitors, HIV, Immunotherapy, Neuroendocrine carcinoma, Small cell cancer",
author = "Muhammad Husnain and Wungki Park and {Carlos Ramos}, Juan and Thomas Johnson and Joseph Chan and Arvind Dasari and Raja Mudad and Peter Hosein",
year = "2018",
month = "7",
day = "9",
doi = "10.1186/s40425-018-0379-x",
language = "English (US)",
volume = "6",
journal = "Journal for ImmunoTherapy of Cancer",
issn = "2051-1426",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Complete response to ipilimumab and nivolumab therapy in a patient with extensive extrapulmonary high-grade small cell carcinoma of the pancreas and HIV infection

AU - Husnain, Muhammad

AU - Park, Wungki

AU - Carlos Ramos, Juan

AU - Johnson, Thomas

AU - Chan, Joseph

AU - Dasari, Arvind

AU - Mudad, Raja

AU - Hosein, Peter

PY - 2018/7/9

Y1 - 2018/7/9

N2 - Background: Immune checkpoint inhibitors (CPIs) have shown promising results in many solid tumors. There are limited data on the safety and efficacy of these drugs in HIV infected patients as they have traditionally been excluded from CPIs clinical trials. Case presentation: We present a case of an HIV-positive patient with extensive extrapulmonary high-grade small cell carcinoma who was treated with dual CPIs (nivolumab and ipilimumab) with a complete response to therapy and with a manageable safety profile. We performed a comprehensive literature review identifying 62 total HIV positive cases treated with CPIs showing this to be a potentially safe option in HIV-positive patients. Conclusion: HIV infection is not an absolute contraindication to CPI therapy. Our case and others provide justification for ongoing trials of CPI therapy in patients with HIV infection, a group that has traditionally been excluded from clinical trials.

AB - Background: Immune checkpoint inhibitors (CPIs) have shown promising results in many solid tumors. There are limited data on the safety and efficacy of these drugs in HIV infected patients as they have traditionally been excluded from CPIs clinical trials. Case presentation: We present a case of an HIV-positive patient with extensive extrapulmonary high-grade small cell carcinoma who was treated with dual CPIs (nivolumab and ipilimumab) with a complete response to therapy and with a manageable safety profile. We performed a comprehensive literature review identifying 62 total HIV positive cases treated with CPIs showing this to be a potentially safe option in HIV-positive patients. Conclusion: HIV infection is not an absolute contraindication to CPI therapy. Our case and others provide justification for ongoing trials of CPI therapy in patients with HIV infection, a group that has traditionally been excluded from clinical trials.

KW - Check point inhibitors

KW - HIV

KW - Immunotherapy

KW - Neuroendocrine carcinoma

KW - Small cell cancer

UR - http://www.scopus.com/inward/record.url?scp=85049833966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049833966&partnerID=8YFLogxK

U2 - 10.1186/s40425-018-0379-x

DO - 10.1186/s40425-018-0379-x

M3 - Article

C2 - 29986769

AN - SCOPUS:85049833966

VL - 6

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

SN - 2051-1426

IS - 1

M1 - 66

ER -